JP4117347B2 - 組織特異的ウイルスベクター - Google Patents

組織特異的ウイルスベクター Download PDF

Info

Publication number: JP4117347B2
Authority: JP; Japan
Prior art keywords: cells; sequence; gene; pse; seq
Prior art date: 1995-06-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP50451797A

Other languages

English (en)

Japanese (ja)

Other versions

JPH11508770A (ja

JPH11508770A5 (2

Inventor

ロバートヘンダーソン，ダニエル

ロドルフシュール，エリック

Original Assignee

セルジェネシス，インコーポレイティド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-27

Filing date

1996-06-26

Publication date

2008-07-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23966983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4117347(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-06-26 Application filed by セルジェネシス，インコーポレイティド filed Critical セルジェネシス，インコーポレイティド

1999-08-03 Publication of JPH11508770A publication Critical patent/JPH11508770A/ja

2004-08-05 Publication of JPH11508770A5 publication Critical patent/JPH11508770A5/ja

2008-07-16 Application granted granted Critical

2008-07-16 Publication of JP4117347B2 publication Critical patent/JP4117347B2/ja

2016-06-26 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000013598 vector Substances 0.000 title claims description 35
241000700605 Viruses Species 0.000 title description 81
241000701161 unidentified adenovirus Species 0.000 claims abstract description 80
206010028980 Neoplasm Diseases 0.000 claims abstract description 33
210000004027 cell Anatomy 0.000 claims description 198
108090000623 proteins and genes Proteins 0.000 claims description 112
108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 33
102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 30
239000003623 enhancer Substances 0.000 claims description 29
230000010076 replication Effects 0.000 claims description 23
238000012217 deletion Methods 0.000 claims description 20
230000037430 deletion Effects 0.000 claims description 20
230000012010 growth Effects 0.000 claims description 19
108700019146 Transgenes Proteins 0.000 claims description 14
239000002773 nucleotide Substances 0.000 claims description 13
125000003729 nucleotide group Chemical group 0.000 claims description 13
108700009124 Transcription Initiation Site Proteins 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
238000000338 in vitro Methods 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
210000005267 prostate cell Anatomy 0.000 claims description 6
230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 5
231100000433 cytotoxic Toxicity 0.000 claims description 4
230000001472 cytotoxic effect Effects 0.000 claims description 4
210000004962 mammalian cell Anatomy 0.000 claims description 3
108010071652 human kallikrein-related peptidase 3 Proteins 0.000 claims 4
102000007579 human kallikrein-related peptidase 3 Human genes 0.000 claims 2
108700028146 Genetic Enhancer Elements Proteins 0.000 claims 1
230000002068 genetic effect Effects 0.000 abstract description 10
108091023040 Transcription factor Proteins 0.000 abstract description 8
102000040945 Transcription factor Human genes 0.000 abstract description 8
230000002103 transcriptional effect Effects 0.000 abstract description 7
230000033228 biological regulation Effects 0.000 abstract description 3
231100000135 cytotoxicity Toxicity 0.000 abstract description 3
230000003013 cytotoxicity Effects 0.000 abstract description 3
230000001419 dependent effect Effects 0.000 abstract description 3
230000029812 viral genome replication Effects 0.000 abstract description 3
230000000977 initiatory effect Effects 0.000 abstract description 2
230000009826 neoplastic cell growth Effects 0.000 abstract 1
241001135569 Human adenovirus 5 Species 0.000 description 85
102000039446 nucleic acids Human genes 0.000 description 82
108020004707 nucleic acids Proteins 0.000 description 82
150000007523 nucleic acids Chemical class 0.000 description 82
239000013612 plasmid Substances 0.000 description 70
239000013615 primer Substances 0.000 description 66
239000012634 fragment Substances 0.000 description 42
230000014509 gene expression Effects 0.000 description 42
101150075174 E1B gene Proteins 0.000 description 35
238000003752 polymerase chain reaction Methods 0.000 description 34
108020004414 DNA Proteins 0.000 description 31
208000015181 infectious disease Diseases 0.000 description 25
230000035897 transcription Effects 0.000 description 25
238000013518 transcription Methods 0.000 description 25
102000004169 proteins and genes Human genes 0.000 description 22
239000003981 vehicle Substances 0.000 description 20
230000003612 virological effect Effects 0.000 description 19
238000003780 insertion Methods 0.000 description 16
230000037431 insertion Effects 0.000 description 16
241000282693 Cercopithecidae Species 0.000 description 14
230000002238 attenuated effect Effects 0.000 description 14
238000002744 homologous recombination Methods 0.000 description 14
230000006801 homologous recombination Effects 0.000 description 14
210000002307 prostate Anatomy 0.000 description 14
230000035772 mutation Effects 0.000 description 13
108091027981 Response element Proteins 0.000 description 12
230000001105 regulatory effect Effects 0.000 description 12
108091026890 Coding region Proteins 0.000 description 11
241000699670 Mus sp. Species 0.000 description 11
238000003556 assay Methods 0.000 description 11
230000000694 effects Effects 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
238000004806 packaging method and process Methods 0.000 description 11
XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 9
229960004413 flucytosine Drugs 0.000 description 9
230000005026 transcription initiation Effects 0.000 description 9
230000002950 deficient Effects 0.000 description 8
238000002703 mutagenesis Methods 0.000 description 8
231100000350 mutagenesis Toxicity 0.000 description 8
229940002612 prodrug Drugs 0.000 description 8
239000000651 prodrug Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
238000010276 construction Methods 0.000 description 7
230000002458 infectious effect Effects 0.000 description 7
229930027917 kanamycin Natural products 0.000 description 7
229960000318 kanamycin Drugs 0.000 description 7
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
229930182823 kanamycin A Natural products 0.000 description 7
239000002502 liposome Substances 0.000 description 7
238000011144 upstream manufacturing Methods 0.000 description 7
101710199711 Early E1A protein Proteins 0.000 description 6
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
101710087110 ORF6 protein Proteins 0.000 description 6
108700026244 Open Reading Frames Proteins 0.000 description 6
108700005077 Viral Genes Proteins 0.000 description 6
239000003098 androgen Substances 0.000 description 6
238000010367 cloning Methods 0.000 description 6
230000029087 digestion Effects 0.000 description 6
229960002949 fluorouracil Drugs 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000002609 medium Substances 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
238000000034 method Methods 0.000 description 6
239000002245 particle Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
229940124597 therapeutic agent Drugs 0.000 description 6
238000001890 transfection Methods 0.000 description 6
101150026402 DBP gene Proteins 0.000 description 5
230000004543 DNA replication Effects 0.000 description 5
238000012408 PCR amplification Methods 0.000 description 5
108020005202 Viral DNA Proteins 0.000 description 5
230000027455 binding Effects 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
210000003292 kidney cell Anatomy 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
238000012546 transfer Methods 0.000 description 5
102000052510 DNA-Binding Proteins Human genes 0.000 description 4
101710096438 DNA-binding protein Proteins 0.000 description 4
108700039691 Genetic Promoter Regions Proteins 0.000 description 4
101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
230000000981 bystander Effects 0.000 description 4
230000030833 cell death Effects 0.000 description 4
230000007547 defect Effects 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000026683 transduction Effects 0.000 description 4
238000010361 transduction Methods 0.000 description 4
230000014616 translation Effects 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
102000000311 Cytosine Deaminase Human genes 0.000 description 3
108010080611 Cytosine Deaminase Proteins 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
101150066038 E4 gene Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
108700026226 TATA Box Proteins 0.000 description 3
108010067390 Viral Proteins Proteins 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
210000000692 cap cell Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
230000002147 killing effect Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
238000001243 protein synthesis Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
230000009261 transgenic effect Effects 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
230000010474 transient expression Effects 0.000 description 3
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 2
101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 2
101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 2
101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 2
101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 2
101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 2
101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 2
102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 2
101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 2
101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 2
101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 2
101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 2
101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 2
101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 2
101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 2
101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 2
101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 2
102000053642 Catalytic RNA Human genes 0.000 description 2
108090000994 Catalytic RNA Proteins 0.000 description 2
101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
108010053187 Diphtheria Toxin Proteins 0.000 description 2
101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 2
101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 2
101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 2
101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 2
101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 2
101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 2
101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 2
101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 2
101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 2
101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 2
101000833492 Homo sapiens Jouberin Proteins 0.000 description 2
101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 2
241000598171 Human adenovirus sp. Species 0.000 description 2
102100024407 Jouberin Human genes 0.000 description 2
101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 2
101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 2
101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 2
101710128836 Large T antigen Proteins 0.000 description 2
101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 2
101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 2
101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 2
101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 2
108010002747 Pfu DNA polymerase Proteins 0.000 description 2
101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 2
101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 2
101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 2
241001068295 Replication defective viruses Species 0.000 description 2
101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 2
101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 2
101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 2
101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 2
101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 2
101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 2
101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 2
101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 2
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 2
101710135104 Uncharacterized protein p6 Proteins 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 2
101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000035508 accumulation Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
101150055766 cat gene Proteins 0.000 description 2
230000022534 cell killing Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
206010013023 diphtheria Diseases 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000005170 neoplastic cell Anatomy 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000004853 protein function Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
239000002356 single layer Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
231100000057 systemic toxicity Toxicity 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
101150014742 AGE1 gene Proteins 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
102100031725 Cortactin-binding protein 2 Human genes 0.000 description 1
230000003682 DNA packaging effect Effects 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
101150082674 E2 gene Proteins 0.000 description 1
102000001388 E2F Transcription Factors Human genes 0.000 description 1
108010093502 E2F Transcription Factors Proteins 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
101150064015 FAS gene Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
101150007425 L4 gene Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
108010086093 Mung Bean Nuclease Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
108010044068 Polyomavirus Transforming Antigens Proteins 0.000 description 1
101710164463 Preterminal protein Proteins 0.000 description 1
101710197985 Probable protein Rev Proteins 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
108050007496 Shikimate kinase 2 Proteins 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
101100038645 Streptomyces griseus rppA gene Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108010044281 TATA-Box Binding Protein Proteins 0.000 description 1
102000006467 TATA-Box Binding Protein Human genes 0.000 description 1
102400001320 Transforming growth factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
201000004484 acute conjunctivitis Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000069 breast epithelial cell Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
244000309466 calf Species 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
230000005101 cell tropism Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
239000003145 cytotoxic factor Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
239000003966 growth inhibitor Substances 0.000 description 1
230000007773 growth pattern Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000007446 host cell death Effects 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
210000002490 intestinal epithelial cell Anatomy 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940055729 papain Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
208000017497 prostate disease Diseases 0.000 description 1
210000000064 prostate epithelial cell Anatomy 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
150000003515 testosterones Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000013414 tumor xenograft model Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
-1 tyrosine amino acid Chemical class 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
210000003501 vero cell Anatomy 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000001018 virulence Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Virology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

JP50451797A 1995-06-27 1996-06-26 組織特異的ウイルスベクター Expired - Fee Related JP4117347B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/495,034 US5698443A (en)	1995-06-27	1995-06-27	Tissue specific viral vectors
US08/495,034		1995-06-27
PCT/US1996/010838 WO1997001358A1 (en)	1995-06-27	1996-06-26	Tissue specific viral vectors

Publications (3)

Publication Number	Publication Date
JPH11508770A JPH11508770A (ja)	1999-08-03
JPH11508770A5 JPH11508770A5 (2)	2004-08-05
JP4117347B2 true JP4117347B2 (ja)	2008-07-16

Family

ID=23966983

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP50451797A Expired - Fee Related JP4117347B2 (ja)	1995-06-27	1996-06-26	組織特異的ウイルスベクター

Country Status (10)

Country	Link
US (2)	US5698443A (2)
EP (1)	EP0844888B1 (2)
JP (1)	JP4117347B2 (2)
AT (1)	ATE295739T1 (2)
AU (1)	AU729648B2 (2)
CA (1)	CA2222457A1 (2)
DE (1)	DE69634752T2 (2)
ES (1)	ES2242196T3 (2)
MX (1)	MX9800145A (2)
WO (1)	WO1997001358A1 (2)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057299A (en) *	1994-01-13	2000-05-02	Calydon, Inc.	Tissue-specific enhancer active in prostate
US5830686A (en) *	1994-01-13	1998-11-03	Calydon	Tissue-specific enhancer active in prostate
US5998205A (en)	1994-11-28	1999-12-07	Genetic Therapy, Inc.	Vectors for tissue-specific replication
US6638762B1 (en) *	1994-11-28	2003-10-28	Genetic Therapy, Inc.	Tissue-vectors specific replication and gene expression
KR100470180B1 (ko)	1995-06-15	2005-02-04	크루셀 홀란드 비.브이.	유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
FR2735789B1 (fr) *	1995-06-23	1997-07-25	Centre Nat Rech Scient	Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US6676935B2 (en) *	1995-06-27	2004-01-13	Cell Genesys, Inc.	Tissue specific adenoviral vectors
US6254862B1 (en)	1997-03-03	2001-07-03	Calydon, Inc.	Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US7001764B2 (en) *	1995-06-27	2006-02-21	Cell Genesys, Inc.	Compositions comprising tissue specific adenoviral vectors
US6197293B1 (en) *	1997-03-03	2001-03-06	Calydon, Inc.	Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US7011976B1 (en)	1997-03-03	2006-03-14	Calydon, Inc.	Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US20020068049A1 (en) *	1998-09-10	2002-06-06	Henderson Daniel R.	Tissue specific adenoviral vectors
WO1997035993A2 (en) *	1996-03-27	1997-10-02	The Regents Of The University Of California	Psa positive regulating (psar) sequences and uses thereof
AUPO023496A0 (en) *	1996-05-31	1996-06-27	Commonwealth Scientific And Industrial Research Organisation	Modified small RNA viruses
US6610839B1 (en)	1997-08-14	2003-08-26	Geron Corporation	Promoter for telomerase reverse transcriptase
US5772993A (en) *	1997-01-21	1998-06-30	The University Of Virginia Patent Foundation	Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
US6403370B1 (en) *	1997-02-10	2002-06-11	Genstar Therapeutics Corporation	Oncolytic/immunogenic complementary-adenoviral vector system
US6100444A (en) *	1997-02-11	2000-08-08	University Of Rochester Medical Center	Prostate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigen
WO1998039464A2 (en) *	1997-03-03	1998-09-11	Cell Genesys, Inc.	Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
JP2002514075A (ja) *	1997-03-03	2002-05-14	セルジェネシス，インコーポレイティド	癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法
EP1905837A1 (en) *	1997-03-03	2008-04-02	Cell Genesys, Inc.	Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US6432700B1 (en) *	1997-03-03	2002-08-13	Cell Genesys, Inc.	Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
IL120485A0 (en) *	1997-03-19	1997-07-13	Yeda Res & Dev	Modulators of the function of receptors of the TNF/NGF receptor family and other proteins
JP4812914B2 (ja) *	1997-06-23	2011-11-09	ユニバーシティオブサスカチュワン	ウシアデノウイルスタイプ３ゲノム
AU8692598A (en)	1997-08-04	1999-02-22	Calydon, Inc.	A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
US6348450B1 (en)	1997-08-13	2002-02-19	The Uab Research Foundation	Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030125278A1 (en) *	1997-08-13	2003-07-03	Tang De-Chu C.	Immunization of animals by topical applications of a salmonella-based vector
US6706693B1 (en)	1997-08-13	2004-03-16	The Uab Research Foundation	Vaccination by topical application of genetic vectors
US20030045492A1 (en) *	1997-08-13	2003-03-06	Tang De-Chu C.	Vaccination by topical application of recombinant vectors
US6716823B1 (en)	1997-08-13	2004-04-06	The Uab Research Foundation	Noninvasive genetic immunization, expression products therefrom, and uses thereof
EP1015003A1 (en) *	1997-09-19	2000-07-05	Johnson & Johnson Research Pty Ltd.	Transgenic autologous t-cell therapy in humans, and related compositions and kits
US7378244B2 (en) *	1997-10-01	2008-05-27	Geron Corporation	Telomerase promoters sequences for screening telomerase modulators
US7780962B2 (en) *	1997-10-09	2010-08-24	Wellstat Biologics Corporation	Treatment of neoplasms with RNA viruses
US20030044384A1 (en) *	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
US7470426B1 (en) *	1997-10-09	2008-12-30	Wellstat Biologics Corporation	Treatment of neoplasms with viruses
WO1999043697A1 (en) *	1998-02-25	1999-09-02	The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno	Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
EP1097243A1 (en) *	1998-07-14	2001-05-09	Merck & Co., Inc.	Adenoviral based promoter assay
US6900049B2 (en) *	1998-09-10	2005-05-31	Cell Genesys, Inc.	Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US7691370B2 (en) *	1998-10-15	2010-04-06	Canji, Inc.	Selectivity replicating viral vector
US6929946B1 (en) *	1998-11-20	2005-08-16	Crucell Holland B.V.	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US20060024273A1 (en) *	1998-12-30	2006-02-02	Henderson Daniel R	Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US6495130B1 (en)	1998-12-30	2002-12-17	Calydon, Inc.	Target cell-specific adenoviral vectors containing E3 and methods of use thereof
NZ550861A (en) *	1999-04-15	2009-03-31	Wellstat Biologics Corp	Treatment of neoplasms with viruses
US20040009936A1 (en) *	1999-05-03	2004-01-15	Tang De-Chu C.	Vaccine and drug delivery by topical application of vectors and vector extracts
US6913922B1 (en) *	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
AU5470900A (en) *	1999-06-08	2000-12-28	Children's Hospital Of Philadelphia, The	Methods for preventing formation of inhibitory antibodies in the setting of genetherapy
DE19928342A1 (de) *	1999-06-21	2000-12-28	Deutsches Krebsforsch	Vektoren zur gentherapeutischen Tumorbehandlung
US8147822B1 (en)	1999-09-17	2012-04-03	Wellstat Biologics Corporation	Oncolytic virus
WO2001027256A2 (en)	1999-10-14	2001-04-19	The Regents Of The University Of California System	Chimeric transcriptional regulatory element and methods for prostate-targeted gene expression
EP1267839B1 (en) *	2000-03-24	2007-10-03	Biosphere Medical, Inc.	Microspheres for active embolization
US20030212022A1 (en) *	2001-03-23	2003-11-13	Jean-Marie Vogel	Compositions and methods for gene therapy
US6911200B2 (en)	2000-03-24	2005-06-28	Cell Genesys, Inc.	Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US7048920B2 (en) *	2000-03-24	2006-05-23	Cell Genesys, Inc.	Recombinant oncolytic adenovirus for human melanoma
US6692736B2 (en) *	2000-03-24	2004-02-17	Cell Genesys, Inc.	Cell-specific adenovirus vectors comprising an internal ribosome entry site
AU2001245944B2 (en)	2000-03-24	2007-01-18	Cell Genesys, Inc.	Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof
CN1981868A (zh) *	2000-03-31	2007-06-20	拜奥根Idec公司	抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
US7285414B2 (en) *	2000-09-26	2007-10-23	Emory University	Viruses targeted to hypoxic cells and tissues
US20040101825A1 (en) *	2001-09-26	2004-05-27	Van Meir Erwin G.	Viruses targeted to hypoxic cells and tissues
EP1207205A1 (en) *	2000-11-20	2002-05-22	Crucell Holland B.V.	Adenoviral replicons
WO2002042468A2 (en)	2000-11-27	2002-05-30	Geron Corporation	Glycosyltransferase vectors for treating cancer
US8263067B2 (en) *	2000-12-28	2012-09-11	Per Sonne Holm	Adenoviral systems and the uses thereof
JP2004526434A (ja) *	2001-01-23	2004-09-02	アイアールエム・リミテッド・ライアビリティ・カンパニー	診断および治療標的としての前立腺障害において過剰発現される遺伝子
JP2004536572A (ja) *	2001-02-23	2004-12-09	セル・ジェネシス・インコーポレイテッド	新規ベクター構築物
AU2002346084B2 (en) *	2001-07-23	2006-11-16	Onyx Pharmaceuticals, Inc.	Viral mutants that selectively replicate in targeted human cancer cells
US20030099616A1 (en) *	2001-07-25	2003-05-29	Irving John M.	Dual specificity tumor killing vectors driven by the telomerase promoter
CA2469623C (en)	2001-12-12	2012-05-29	F H Faulding & Co Limited	Composition for the preservation of viruses
PL215165B1 (pl) *	2002-04-25	2013-10-31	Crucell Holland Bv	Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego
US20060099178A1 (en)	2002-05-27	2006-05-11	Holm Per S	Novel use of adenoviruses and nucleic acids coding therefor
US7364727B2 (en) *	2002-07-22	2008-04-29	Cell Genesys, Inc.	Metastatic colon cancer specific promoter and uses thereof
US7977049B2 (en)	2002-08-09	2011-07-12	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (en)	2002-08-09	2004-02-09	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050095705A1 (en) *	2003-04-15	2005-05-05	Michael Kadan	Method for production of oncolytic adenoviruses
US20050136035A1 (en) *	2003-06-03	2005-06-23	Derek Ko	Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CA2526120A1 (en) *	2003-06-03	2005-02-24	Cell Genesys, Inc.	Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050079158A1 (en) *	2003-06-05	2005-04-14	Shenzhen Allucks Biotech Co., Ltd.	Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof
DE602004031681D1 (de)	2003-07-21	2011-04-14	Transgene Sa	Multifunktionelle Cytokine
US20050186178A1 (en) *	2003-08-28	2005-08-25	Ennist David L.	Oncolytic adenoviral vectors encoding GM-CSF
US7482156B2 (en) *	2003-10-15	2009-01-27	Cell Genesys, Inc.	Hepatocellular carcinoma specific promoter and uses thereof
EP1689445B1 (de)	2003-11-14	2015-02-25	Per Sonne Holm	Neue verwendung von adenoviren und dafür codierende nukleinsäuren
US7473418B2 (en)	2004-03-25	2009-01-06	Cell Genesys, Inc.	Pan cancer oncolytic vectors and methods of use thereof
US20050271622A1 (en) *	2004-06-03	2005-12-08	Shenzhen Allucks Biotech Co., Ltd.	Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof
GB0416487D0 (en) *	2004-07-23	2004-08-25	Isis Innovation	Modified virus
KR20090006221A (ko) *	2004-07-26	2009-01-14	아스테리온 리미티드	연결체들
US20060062764A1 (en) *	2004-08-25	2006-03-23	Seshidar-Reddy Police	Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
US7524510B2 (en)	2005-02-23	2009-04-28	The Uab Research Foundation	Alkyl-glycoside enhanced vaccination
US20060205080A1 (en) *	2005-03-01	2006-09-14	David Frey	Formulations for therapeutic viruses having enhanced storage stability
KR20140090270A (ko)	2005-05-09	2014-07-16	바이오스피어 메디칼 에스.에이.	마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및 방법
PE20081723A1 (es)	2007-01-30	2008-12-14	Transgene Sa	Vacuna contra el papilomavirus
MX2011007386A (es)	2009-01-20	2011-08-03	Transgene Sa	Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica.
ES2900277T3 (es)	2009-03-20	2022-03-16	Mesoblast Inc	Producción de células pluripotentes reprogramadas
WO2010108908A1 (en)	2009-03-24	2010-09-30	Transgene Sa	Biomarker for monitoring patients
JP5661738B2 (ja)	2009-04-17	2015-01-28	トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅＳ．Ａ．	患者をモニターするためのバイオマーカー
CA2767458A1 (en)	2009-07-10	2011-01-13	Bruce Acres	Biomarker for selecting patients and related methods
GB0919773D0 (en)	2009-11-12	2009-12-30	Univ Nottingham	Induced pluripotent stem cell
CN101899420A (zh) *	2010-01-16	2010-12-01	韩从辉	一种靶向抗前列腺肿瘤的表达超抗原基因的双调控溶瘤腺病毒的制备方法
EP2601212A1 (en)	2010-08-04	2013-06-12	Cizzle Biotechnology Limited	Methods and compounds for the diagnosis and treatment of
GB201016852D0 (en)	2010-10-07	2010-11-17	Univ York	Cell differentiation
GB201102091D0 (en)	2011-02-08	2011-03-23	Univ Sheffield	Antigenic polypeptide
GB201102090D0 (en)	2011-02-08	2011-03-23	Univ Sheffield	Antigenic polypeptide
EP3587455A1 (en)	2012-10-23	2020-01-01	Emory University	Gm-csf and il-4 conjugates, compositions, and methods related thereto
EP3684421A4 (en)	2017-09-18	2021-08-04	Children's Hospital Medical Center	STRONG INSULATOR AND ITS USES IN GENE ADMINISTRATION
WO2020264361A1 (en)	2019-06-28	2020-12-30	Massachusetts Institute Of Technology	Circular strained zymogen compositions and methods of use
JP2023511274A (ja)	2020-01-14	2023-03-17	シンセカインインコーポレイテッド	Ｉｌ２オルソログおよび使用法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL9001828A (nl) *	1990-08-15	1992-03-02	Centraal Diergeneeskundig Inst	Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde.
FR2705686B1 (fr) *	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DE69434594T2 (de) *	1993-10-25	2006-09-21	Canji, Inc., San Diego	Rekombinante adenoviren-vektor und verfahren zur verwendung
US5830686A (en) *	1994-01-13	1998-11-03	Calydon	Tissue-specific enhancer active in prostate
WO1996010838A1 (en) *	1994-09-30	1996-04-11	Matsushita Electric Industrial Co., Ltd.	Apparatus and method for bonding tape
US5919652A (en) *	1994-11-09	1999-07-06	The Regents Of The University Of California	Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
EP0791050B1 (en) *	1994-11-28	2006-02-15	Cell Genesys Inc.	Vectors for tissue-specific replication
CA2206205A1 (en) *	1994-11-28	1996-06-06	Genetic Therapy, Inc.	Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors
US20030026789A1 (en) *	1995-05-03	2003-02-06	Richard J. Gregory	Gene therapy using replication competent targeted adenoviral vectors
WO1996036365A1 (en) *	1995-05-18	1996-11-21	Genetic Therapy, Inc.	Gene therapy of hepatocellular carcinoma through cancer-specific gene expression

1995
- 1995-06-27 US US08/495,034 patent/US5698443A/en not_active Expired - Fee Related
1996
- 1996-06-26 AT AT96923418T patent/ATE295739T1/de not_active IP Right Cessation
- 1996-06-26 DE DE69634752T patent/DE69634752T2/de not_active Expired - Fee Related
- 1996-06-26 AU AU63932/96A patent/AU729648B2/en not_active Ceased
- 1996-06-26 ES ES96923418T patent/ES2242196T3/es not_active Expired - Lifetime
- 1996-06-26 JP JP50451797A patent/JP4117347B2/ja not_active Expired - Fee Related
- 1996-06-26 EP EP96923418A patent/EP0844888B1/en not_active Expired - Lifetime
- 1996-06-26 CA CA002222457A patent/CA2222457A1/en not_active Abandoned
- 1996-06-26 US US08/669,753 patent/US5871726A/en not_active Expired - Fee Related
- 1996-06-26 WO PCT/US1996/010838 patent/WO1997001358A1/en not_active Ceased
1998
- 1998-01-07 MX MX9800145A patent/MX9800145A/es not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2222457A1 (en)	1997-01-16
AU729648B2 (en)	2001-02-08
DE69634752D1 (de)	2005-06-23
EP0844888B1 (en)	2005-05-18
JPH11508770A (ja)	1999-08-03
ATE295739T1 (de)	2005-06-15
WO1997001358A1 (en)	1997-01-16
EP0844888A1 (en)	1998-06-03
DE69634752T2 (de)	2006-01-12
MX9800145A (es)	1998-11-30
US5871726A (en)	1999-02-16
EP0844888A4 (en)	1999-11-03
ES2242196T3 (es)	2005-11-01
US5698443A (en)	1997-12-16
AU6393296A (en)	1997-01-30

Legal Events

Date	Code	Title	Description
2006-04-27	RD02	Notification of acceptance of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20060403
2006-04-27	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060403
2007-08-21	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070821
2007-11-22	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071101
2007-12-10	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071210
2008-01-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071220
2008-02-01	TRDD	Decision of grant or rejection written
2008-02-19	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080219
2008-03-13	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080310
2008-05-02	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2008-05-08	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20110502 Year of fee payment: 3
2011-05-02	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
US5871726A (en)	1999-02-16	Tissue specific and tumor growth supperssion by adenovirus comprising prostate specific antigen
US20030044383A1 (en)	2003-03-06	Tissue specific adenoviral vectors
EP1002103B1 (en)	2007-10-17	A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
US6585968B2 (en)	2003-07-01	Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
EP2403951B1 (en)	2015-09-30	Tumor-selective adenovirus e1a and e1b mutants
US7001764B2 (en)	2006-02-21	Compositions comprising tissue specific adenoviral vectors
ES2258265T3 (es)	2006-08-16	Vectores de replicacion con especificidad tisular.
EP1141363B1 (en)	2007-07-25	Target cell-specific adenoviral vectors containing e3 and methods of use thereof
CA2283231C (en)	2008-05-20	Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US20090258935A1 (en)	2009-10-15	Hybrid adeno-retroviral vector for the transfection of cells
JPH10508491A (ja)	1998-08-25	新規なアデノウイルスベクター、パッケージング細胞系、組換えアデノウイルスおよび方法
JPH09509330A (ja)	1997-09-22	分子間相同組換えによるウイルスベクターの作製方法
JPH10507927A (ja)	1998-08-04	改良されたアデノウイルスおよびその使用法
JP2009028040A (ja)	2009-02-12	非ｃ群アデノウイルスベクター
JP2002525063A (ja)	2002-08-13	細胞状態特異的反応エレメントを含むアデノウイルスベクター及びその使用方法
JP2002514075A (ja)	2002-05-14	癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法
JP2000106875A (ja)	2000-04-18	目的遺伝子の発現を改善するためのアデノウイルスｅ４リ―ディングフレ―ムの使用
US5985846A (en)	1999-11-16	Gene therapy for muscular dystrophy
JP2001521390A (ja)	2001-11-06	増強された持続性のための新規導入遺伝子発現系
JP2002539796A (ja)	2002-11-26	腫瘍細胞誘導転写因子の制御の下にある毒素遺伝子を含む抗新生物ウイルス剤
US7226779B2 (en)	2007-06-05	Hybrid adenoviral vector
US20020068049A1 (en)	2002-06-06	Tissue specific adenoviral vectors
US7011976B1 (en)	2006-03-14	Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
JP2000279178A (ja)	2000-10-10	ウイルスベクター
EP1905837A1 (en)	2008-04-02	Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same